PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.

Saved in:
Bibliographic Details
Title: PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Authors: Moyo TK; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.; Levine Cancer Institute, Charlotte, North Carolina., Kishtagari A; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Villaume MT; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., McMahon B; University of Colorado, Denver, Colorado., Mohan SR; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Stopczynski T; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University, Nashville, Tennessee., Chen SC; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University, Nashville, Tennessee., Fan R; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University, Nashville, Tennessee., Huo Y; Department of Electrical and Computer Engineering, Vanderbilt University School of Medicine, Nashville, Tennessee., Moon H; Department of Electrical and Computer Engineering, Vanderbilt University School of Medicine, Nashville, Tennessee., Tang Y; Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee., Bejan CA; Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee., Childress M; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Anderson I; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Rawling K; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Simons RM; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Moncrief A; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Caza R; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Dugger L; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Collins A; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Dudley CV; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Ferrell PB; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee., Byrne M; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Strickland SA; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Ayers GD; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University, Nashville, Tennessee., Landman BA; Department of Electrical and Computer Engineering, Vanderbilt University School of Medicine, Nashville, Tennessee.; Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee., Mason EF; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee., Mesa RA; Wake Forest Baptist Cancer Center, Winston-Salem, North Carolina., Palmer JM; Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona., Michaelis LC; Medical College of Wisconsin, Madison, Wisconsin., Savona MR; Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jul 05; Vol. 29 (13), pp. 2375-2384.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-22-3192